Myalepta®Triangle

(metreleptin powder for solution for injection)

RISK MINIMISATION: INFORMATION FOR HEALTHCARE PROFESSIONALS


  • Specialist Prescribing Information
  • Package Leaflet
  • Patient Dose Information Card
  • Healthcare Professional Guide
  • How to Prepare and Inject Myalepta correctly Video
  • Patient Care Guide (for patients and carers)
  • Patient Information

Suspected adverse reactions and adverse events should be reported.

Reporting forms and information can be found on the MHRA Yellow Card reporting site or www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse reactions should also be reported to Amryt by calling 00800 4447 4447 or e-mail: medinfo@amrytpharma.com


▼Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Amryt by email to medinfo@amrytpharma.com or by telephoning 00 800 4447 4447.

Amryt and Aegerion Logo

Amryt Pharmaceuticals DAC, 45 Mespil Road, Dublin 4, Ireland. Medical Information details - email: medinfo@amrytpharma.com, phone: 00800 4447 4447

Code: C-MTA/UK/0045   Date of Preparation: February 2022

Terms of Use Imprint Privacy Policy Summary of Product Characteristics 3mg Summary of Product Characteristics 5.8mg Summary of Product Characteristics 11.3mg

© Amryt Pharma 2022.
Myalepta® is a registered trademark of the Amryt group. All rights reserved.

×

Video

Download Video
×

PACKAGE LEAFLETS

Package Leaflet 3mg Package Leaflet 5.8mg Package Leaflet 11.3mg